Neuramedy
www.neuramedy.comWe are researching neuro-degenerative disorder focused on alpha synuclein. Our lead compound is Tomaraliman, a TLR2 agonist for Parkinsons' disease.
Read more
We are researching neuro-degenerative disorder focused on alpha synuclein. Our lead compound is Tomaraliman, a TLR2 agonist for Parkinsons' disease.
Read more
Country
City (Headquarters)
Seoul
Industry
Employees
11-50
Founded
2019
Social
Employees statistics
View all employeesPotential Decision Makers
Co - Chief Executive Officer and Founder at Neuramedy
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Associate Director
Email ****** @****.comPhone (***) ****-****
Technologies
(2)
Reach decision makers at Neuramedy
Free credits every month!
Neuramedy FAQ
Seoul, South Korea
Biotechnology Research
